US3859049A - Blood reference standard and process for blood gas test - Google Patents

Blood reference standard and process for blood gas test Download PDF

Info

Publication number
US3859049A
US3859049A US438866A US43886674A US3859049A US 3859049 A US3859049 A US 3859049A US 438866 A US438866 A US 438866A US 43886674 A US43886674 A US 43886674A US 3859049 A US3859049 A US 3859049A
Authority
US
United States
Prior art keywords
reference standard
blood
fluoride
citrate
hemoglobin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US438866A
Inventor
Arnold G Ware
Edward P Marbach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US438866A priority Critical patent/US3859049A/en
Application granted granted Critical
Publication of US3859049A publication Critical patent/US3859049A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/795—Porphyrin- or corrin-ring-containing peptides
    • G01N2333/805—Haemoglobins; Myoglobins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/70—Blood gas control solutios containing dissolved oxygen, bicarbonate and the like
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/102499—Blood gas standard or control
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/105831—Protein or peptide standard or control [e.g., hemoglobin, etc.]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/108331—Preservative, buffer, anticoagulant or diluent

Definitions

  • Blood gas tests are performed in most hospital laboratories on an emergency basis forthe purpose of diagnosing and treating abnormalities of pulmonary function and acid base balance.
  • the three parameters are blood pH, pCO and p
  • blood is drawn from the patient and introduced promptly into specialized equipment containing electrodes specific for each of the three blood-gas componetns. Since the blood sample deteriorates rapidly, it must be analyzed promptly, or within several hours if iced. As time progresses, however, the pH of the blood sample decreases, the pCO increases, and the p0 decreases as a result of cellular metabolism. There is no recognized process in the prior art for preventing these changes from occurring in stored blood samples.
  • the present invention is directed to a means of stabilizing the aforesaid components in blood, or a suspension of blood cells in an appropriate media, so as to facilitate the use of stored blood for standardizing and controlling the blood gas equipment.
  • the process of the invention may also be used to stabilize, for example, a mixture of hemoglobin and buffer salts, which does not involve blood cells.
  • the stabilizing agents are fluoride, citrate and iodoacetate. Each of these substances prevents a portion of the cellular metabolic processes which cause the changes in blood gases noted previously: fluoride by binding magnesium; citrate and iodoacetate by inhibiting different pathways in the metabolic processes.
  • Fresh blood is drawn and mixed with a solution containing concentrates of sodium fluoride, citrate and iodoacetic or fluoroacetic acid in sufficient quantity to yield the final blood concentrations mentioned above.
  • a solution containing concentrates of sodium fluoride, citrate and iodoacetic or fluoroacetic acid in sufficient quantity to yield the final blood concentrations mentioned above.
  • 25 milligrams of sodium fluoride and 93 milligrams of iodoacetic or fluoroacetic acid are dissolved in 10 ml of water and then mixed with 250 ml of blood.
  • the citrate is also dissolved in water and mixed with the blood.
  • These anions may be added in combination with any cation so long as the pH is ad justed to approximately 7.4 37C. Following this the blood is stored in air tight containers ideally leaving little or no air space.
  • fresh red cells are washed and suspended in an albumen glucose solution containing concentrates of sodium fluoride and citrate in sufficient quantity to yield the concentrations set forth above.
  • a mixture of hemoglobin (not cells) and buffer salts may be treated in the manner described above to stabilize the pH at about 7.40, the pCO at about 40 mm, and the p0 at about 80mm.
  • Glycerol may be added to increase the viscosity of the mixture to about 3.5 centipoise, that of normal whole blood, and to act as a preservative.
  • About a 50 percent solution at 37 C would have a viscosity of 3.5 centipoise, a percent solution would have better preserving power, but the viscosity would be 9.4 centipoise.
  • a process of providing a reference standard which consists of deriving a reference standard containing blood, blood cells, hemoglobin, or the like, dissolving sodium fluoride and iodoacetic or fluroacetic acid in water, and mixing the resulting solution with the reference standard.
  • a process for providing a reference standard which consists of washing fresh red cells, dissolving sodium fluoride and citrate in an albumen glucose solution, and suspending the red cells in the solution.

Abstract

A stable blood reference standard and control for blood gas tests which includes the use of fluoride, citrate and iodoacetate.

Description

United States Patent Ware et a1.
Jan. 7, 1975 BLOOD REFERENCE STANDARD AND PROCESS FOR BLOOD GAS TEST Inventors: Arnold G. Ware, 4044 Park Vista pn, Pasadena, Calif. 91107; Edward P. Marbach, 4607 Marwood Dr., Los Angeles, Calif.
Filed: Feb. 1, 1974 Appl. No.: 438,866
Related US. Application Data Continuation-impart of Ser. No. 397,347, Sept. 14, 1973, abandoned.
US. Cl. 23/230 B, 252/408 Int. Cl. GOln 33/16 [58] Field of Search 23/230 B; 252/408; 424/11 Primary Examiner-R E. Serwin Attorney, Agent, or Firm-Jessup & Beecher [57] ABSTRACT A stable blood reference standard and control for blood gas tests which includes the use of fluoride, citrate and iodoacetate.
11 Claims, N0 Drawings BLOOD REFERENCE STANDARD AND PROCESS FOR BLOOD GAS TEST This is a continuation-in-part of Copending application Ser. No. 397,347, filed Sept. 14, 1973, and now abandoned.
BACKGROUND OF THE DISCLOSURE Blood gas tests are performed in most hospital laboratories on an emergency basis forthe purpose of diagnosing and treating abnormalities of pulmonary function and acid base balance. The three parameters are blood pH, pCO and p In performing the test, blood is drawn from the patient and introduced promptly into specialized equipment containing electrodes specific for each of the three blood-gas componetns. Since the blood sample deteriorates rapidly, it must be analyzed promptly, or within several hours if iced. As time progresses, however, the pH of the blood sample decreases, the pCO increases, and the p0 decreases as a result of cellular metabolism. There is no recognized process in the prior art for preventing these changes from occurring in stored blood samples.
Present day blood gas equipment is standardized and controlled by cumbersome procedures using buffers for pH, and gases for pCO and p0 Blood specimens of known pH, pCO and p0 would be preferable for this purpose. However, the instability of these components in blood has made this approach impractical in the prior art.
DETAILED DESCRIPTION OF THE INVENTION The present invention is directed to a means of stabilizing the aforesaid components in blood, or a suspension of blood cells in an appropriate media, so as to facilitate the use of stored blood for standardizing and controlling the blood gas equipment. The process of the invention may also be used to stabilize, for example, a mixture of hemoglobin and buffer salts, which does not involve blood cells. The stabilizing agents are fluoride, citrate and iodoacetate. Each of these substances prevents a portion of the cellular metabolic processes which cause the changes in blood gases noted previously: fluoride by binding magnesium; citrate and iodoacetate by inhibiting different pathways in the metabolic processes.
It has been found that combinations of the abovementioned inhibitors when added to blood or a suspension of blood cells, or a mixture of hemogloblin, stabilize the blood gases for periods of 30 days or longer when stored in closed containers under refrigeration.
The following example will further illustrate the present invention although the invention is not limited to this specific example which is provided by way of illustration and not limitation.
Fluoride 25 millimolar Citrate l2 millimolar iodoacetate 5 millimolar (fluoroacetate may be substituted for iodoacetate) It has been found that the concentrations listed above have been most efficient. However, it has also been found that the listed components may be varied considerably in concentration and in relation with each other without appreciably varying the blood gas stabilizing effect. For example, the following ranges of concentration have been found to be permissible, without significantly reducing the blood gas stabilizing effect.
Fluoride 10 to I00 millimolar Citrate 3 to 50 millimolar lodoacetate l to l0 millimolar In carrying out the process of the invention in accordance with one particular example, the following steps are presented:
Fresh blood is drawn and mixed with a solution containing concentrates of sodium fluoride, citrate and iodoacetic or fluoroacetic acid in sufficient quantity to yield the final blood concentrations mentioned above. For example, 25 milligrams of sodium fluoride and 93 milligrams of iodoacetic or fluoroacetic acid are dissolved in 10 ml of water and then mixed with 250 ml of blood. The citrate is also dissolved in water and mixed with the blood. These anions may be added in combination with any cation so long as the pH is ad justed to approximately 7.4 37C. Following this the blood is stored in air tight containers ideally leaving little or no air space. After 2 weeks at refrigerated temperature the pH, pCO and p0 are stabilized and remain unchanged for 30 days or longer if kept under refrigeration. In contrast, blood specimens without these preservatives show a progressive drop in pH and p0 and increase in pCO Such changes are sufficient in magnitude to render untreated blood unsatisfactory as a blood gas standard or control.
As another example, fresh red cells are washed and suspended in an albumen glucose solution containing concentrates of sodium fluoride and citrate in sufficient quantity to yield the concentrations set forth above.
As another example, a mixture of hemoglobin (not cells) and buffer salts may be treated in the manner described above to stabilize the pH at about 7.40, the pCO at about 40 mm, and the p0 at about 80mm. Glycerol may be added to increase the viscosity of the mixture to about 3.5 centipoise, that of normal whole blood, and to act as a preservative. About a 50 percent solution at 37 C would have a viscosity of 3.5 centipoise, a percent solution would have better preserving power, but the viscosity would be 9.4 centipoise.
It will be readily apparent to those skilled in the particular art under consideration that other examples of the invention described herein may be devised from an understanding of the foregoing specification without departing from the spirit and scope of the invention. It is intended in the following claims to cover all such modifications, variations and adaptations which are included within the scope of the invention.
What is claimed is:
l. A reference standard containing blood, blood cells, hemoglobin, or the like, reconstituted by the addition of a fluoride and an iodoacetate or a fluoroacetate.
2. A reference standard defined in claim 1, in which the fluoride and iodoacetate or fluoroacetate are included with a concentration for the fluoride substantially in a range of 10-100 millimolar, and with a concentration for the iodoacetate or fluoroacetate substantially in a range of l to 10 millimolar.
3. The reference standard defined in claim 1, and which also contains a citrate.
4. The reference standard defined in claim 2, and which further includes a citrate substantially in a range of 3 to 50 millimolar.
5. The reference standard defined in claim 1, in which the fluoride is sodium fluoride and the iodoacetate or fluoroacetate is iodoacetic or fluoroacetic acid.
6. The reference standard defined in claim 1, which comprises hemoglobin and glycerol in proportions to provide a viscosity of the order of 3.5 centipoise.
7. A process of providing a reference standard which consists of deriving a reference standard containing blood, blood cells, hemoglobin, or the like, dissolving sodium fluoride and iodoacetic or fluroacetic acid in water, and mixing the resulting solution with the reference standard.
8. The process defined in claim 7, and which further comprises the step of dissolving citrate in water and mixing the resulting solution with the reference standard.
9. The process defined in claim 7, in which 25 milligrams of sodium fluoride and 93 milligrams of iodoacetic acid are dissolved in 10 ml of water and then mixed with 25 ml of the reference standard or in multiples or sub-multiples thereof.
10. A process for providing a reference standard which consists of washing fresh red cells, dissolving sodium fluoride and citrate in an albumen glucose solution, and suspending the red cells in the solution.
11. The process defined in claim 7, which comprises deriving a unit of hemoglobin, and adding glycerol to the hemoglobin to increase the viscosity thereof to the order of 3.5 centipoise.

Claims (11)

1. A REFERENCE STANDARD CONTAINING BLOOD, BLOOD CELLS, HEMOGLOBIN, OR THE LIKE, RECONSTITUED BY THE ADDITION OF A FLUORIDE AND AN IODOACETATE OR FLUOROACETATE.
2. A reference standard defined in claim 1, in which the fluoride and iodoacetate or fluoroacetate are included with a concentration for the fluoride substantially in a range of 10-100 millimolar, and with a concentration for the iodoacetate or fluoroacetate substantially in a range of 1 to 10 millimolar.
3. The reference standard defined in claim 1, and which also contains a citrate.
4. The reference standard defined in claim 2, and which further includes a citrate substantially in a range of 3 to 50 millimolar.
5. The reference standard defined in claim 1, in which the fluoride is sodium fluoride and the iodoacetate or fluoroacetate is iodoacetic or fluoroacetic acid.
6. The reference standard defined in claim 1, which comprises hemoglobin and glycerol in proportions to provide a viscosity of the order of 3.5 centipoise.
7. A process of providing a reference standard which consists of deriving a reference standard containing blood, blood cells, hemoglobin, or the like, dissolving sodium fluoride and iodoacetic or fluroacetic acid in water, and mixing the resulting solution with the reference standard.
8. The process defined in claim 7, and whiCh further comprises the step of dissolving citrate in water and mixing the resulting solution with the reference standard.
9. The process defined in claim 7, in which 25 milligrams of sodium fluoride and 93 milligrams of iodoacetic acid are dissolved in 10 ml of water and then mixed with 25 ml of the reference standard or in multiples or sub-multiples thereof.
10. A process for providing a reference standard which consists of washing fresh red cells, dissolving sodium fluoride and citrate in an albumen glucose solution, and suspending the red cells in the solution.
11. The process defined in claim 7, which comprises deriving a unit of hemoglobin, and adding glycerol to the hemoglobin to increase the viscosity thereof to the order of 3.5 centipoise.
US438866A 1973-09-14 1974-02-01 Blood reference standard and process for blood gas test Expired - Lifetime US3859049A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US438866A US3859049A (en) 1973-09-14 1974-02-01 Blood reference standard and process for blood gas test

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39734773A 1973-09-14 1973-09-14
US438866A US3859049A (en) 1973-09-14 1974-02-01 Blood reference standard and process for blood gas test

Publications (1)

Publication Number Publication Date
US3859049A true US3859049A (en) 1975-01-07

Family

ID=27015859

Family Applications (1)

Application Number Title Priority Date Filing Date
US438866A Expired - Lifetime US3859049A (en) 1973-09-14 1974-02-01 Blood reference standard and process for blood gas test

Country Status (1)

Country Link
US (1) US3859049A (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3977995A (en) * 1974-10-17 1976-08-31 Baxter Laboratories, Inc. Calibrating fluid for blood cell counting and hemoglobin determination
US4001142A (en) * 1975-07-25 1977-01-04 Warner-Lambert Company Blood gas control
US4040785A (en) * 1976-10-18 1977-08-09 Technicon Instruments Corporation Lysable blood preservative composition
US4054488A (en) * 1975-08-14 1977-10-18 Marbach Edward P Preservation of glucose in blood samples
US4102810A (en) * 1975-01-13 1978-07-25 Coulter Electronics, Inc. Stabilized hematological reagent solutions
US4116336A (en) * 1975-05-30 1978-09-26 Radiometer A/S Package containing a reference liquid for blood gas equipment
US4126575A (en) * 1977-11-22 1978-11-21 Louderback Allan Lee Blood control standard
US4151108A (en) * 1976-01-27 1979-04-24 Radiometer A/S Reference liquid for blood gas equipment
US4163734A (en) * 1975-05-30 1979-08-07 Radiometer A/S Reference liquid for blood gas equipment
US4279775A (en) * 1979-12-31 1981-07-21 Louderback Allan Lee Blood gas control
US4351743A (en) * 1976-04-07 1982-09-28 Yoshikazu Hashimoto Dilute standard gases prepared by utilizing buffered solution, method for preparation thereof and apparatus therefor
WO1983003902A1 (en) * 1982-05-03 1983-11-10 American Hospital Supply Corporation Blood gas control
US4469792A (en) * 1980-12-31 1984-09-04 Allied Corporation Blood gas calibration and control fluid utilizing stroma-free hemoglobin
US4485174A (en) * 1982-09-29 1984-11-27 Instrumentation Laboratory Inc. Hemoglobin-based blood gas control
EP0181033A1 (en) * 1984-11-05 1986-05-14 Akzo N.V. Control for blood gas analyzers and hemoglobin analysis
US5308767A (en) * 1986-10-31 1994-05-03 Fuji Photo Film Co., Ltd. Method for control or calibration in a chemical analytical determination
US5422278A (en) * 1987-11-17 1995-06-06 Dade International Inc. Blood gas/electrolyte calibrator and quality controls
US5547874A (en) * 1986-10-31 1996-08-20 Fuji Photo Film Co., Ltd. Method for control or calibration in a chemical analytical determination
US5697366A (en) * 1995-01-27 1997-12-16 Optical Sensors Incorporated In situ calibration system for sensors located in a physiologic line
EP2116611A1 (en) * 2007-01-30 2009-11-11 Arkray, Inc. Measurement method for hba1c

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3466249A (en) * 1967-02-13 1969-09-09 Baxter Laboratories Inc Blood serum reference standard for multi-automated analytical procedures
US3629142A (en) * 1969-12-08 1971-12-21 Edward P Marbach Reference standard blood serum for the calibration of automatic blood serum analyzing apparatus
US3681255A (en) * 1970-09-03 1972-08-01 Gen Electric Process for the preparation of liquid calibration fluids

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3466249A (en) * 1967-02-13 1969-09-09 Baxter Laboratories Inc Blood serum reference standard for multi-automated analytical procedures
US3629142A (en) * 1969-12-08 1971-12-21 Edward P Marbach Reference standard blood serum for the calibration of automatic blood serum analyzing apparatus
US3681255A (en) * 1970-09-03 1972-08-01 Gen Electric Process for the preparation of liquid calibration fluids

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3977995A (en) * 1974-10-17 1976-08-31 Baxter Laboratories, Inc. Calibrating fluid for blood cell counting and hemoglobin determination
US4102810A (en) * 1975-01-13 1978-07-25 Coulter Electronics, Inc. Stabilized hematological reagent solutions
US4116336A (en) * 1975-05-30 1978-09-26 Radiometer A/S Package containing a reference liquid for blood gas equipment
US4163734A (en) * 1975-05-30 1979-08-07 Radiometer A/S Reference liquid for blood gas equipment
US4001142A (en) * 1975-07-25 1977-01-04 Warner-Lambert Company Blood gas control
DK152520B (en) * 1975-07-25 1988-03-07 Warner Lambert Co REFERENCE SYSTEM FOR BLOOD GAS MEASUREMENTS AND PROCEDURES FOR PRODUCING THE SYSTEM
US4054488A (en) * 1975-08-14 1977-10-18 Marbach Edward P Preservation of glucose in blood samples
US4151108A (en) * 1976-01-27 1979-04-24 Radiometer A/S Reference liquid for blood gas equipment
US4351743A (en) * 1976-04-07 1982-09-28 Yoshikazu Hashimoto Dilute standard gases prepared by utilizing buffered solution, method for preparation thereof and apparatus therefor
US4040785A (en) * 1976-10-18 1977-08-09 Technicon Instruments Corporation Lysable blood preservative composition
US4126575A (en) * 1977-11-22 1978-11-21 Louderback Allan Lee Blood control standard
US4279775A (en) * 1979-12-31 1981-07-21 Louderback Allan Lee Blood gas control
US4469792A (en) * 1980-12-31 1984-09-04 Allied Corporation Blood gas calibration and control fluid utilizing stroma-free hemoglobin
WO1983003902A1 (en) * 1982-05-03 1983-11-10 American Hospital Supply Corporation Blood gas control
US4458021A (en) * 1982-05-03 1984-07-03 American Hospital Supply Corporation Blood gas control
US4485174A (en) * 1982-09-29 1984-11-27 Instrumentation Laboratory Inc. Hemoglobin-based blood gas control
US4711852A (en) * 1984-11-05 1987-12-08 Akzo N.V. Control for blood gas analyzers and hemoglobin analysis
EP0181033A1 (en) * 1984-11-05 1986-05-14 Akzo N.V. Control for blood gas analyzers and hemoglobin analysis
US5308767A (en) * 1986-10-31 1994-05-03 Fuji Photo Film Co., Ltd. Method for control or calibration in a chemical analytical determination
US5547874A (en) * 1986-10-31 1996-08-20 Fuji Photo Film Co., Ltd. Method for control or calibration in a chemical analytical determination
US5422278A (en) * 1987-11-17 1995-06-06 Dade International Inc. Blood gas/electrolyte calibrator and quality controls
US5518929A (en) * 1987-11-17 1996-05-21 Dade International Inc. Method of making a blood gas/electrolyte control
US5697366A (en) * 1995-01-27 1997-12-16 Optical Sensors Incorporated In situ calibration system for sensors located in a physiologic line
US5976085A (en) * 1995-01-27 1999-11-02 Optical Sensors Incorporated In situ calibration system for sensors located in a physiologic line
EP2116611A1 (en) * 2007-01-30 2009-11-11 Arkray, Inc. Measurement method for hba1c
US20100178659A1 (en) * 2007-01-30 2010-07-15 Arkray, Inc. METHOD OF MEASURING HbA1c
US8008085B2 (en) * 2007-01-30 2011-08-30 Arkray, Inc. Method of measuring HbA1c
EP2116611A4 (en) * 2007-01-30 2012-01-18 Arkray Inc Measurement method for hba1c
JP5324918B2 (en) * 2007-01-30 2013-10-23 アークレイ株式会社 HbA1c measurement method

Similar Documents

Publication Publication Date Title
US3859049A (en) Blood reference standard and process for blood gas test
Quick On the constitution of prothrombin
Hooper et al. Blood Volume Studies: I. Experimental Control of a Dye Blood Volume Method
Nelson et al. Studies on blood ammonia in normal and shock states
BoCk et al. Changes in intracellular Mg adenosine triphosphate and ionized Mg2+ during blood storage: detection by 31P nuclear magnetic resonance spectroscopy
Moll et al. The diffusion coefficient of haemoglobin
EP0012184A1 (en) Hemolytic solution, application of such a solution for determining the presence of glucose in blood, and hemolytic process
Abraham et al. Effect of vitamin B-6 on plasma and red blood cell magnesium levels in premenopausal women
Ferguson et al. The transport of CO2 in the blood of certain freshwater fishes
Villamil et al. Extracellular space and the ionic distribution in the isolated arterial wall
Tomoda et al. Glycolysis of red cells suspended in solutions of impermeable solutes: intracellular pH and glycolysis
Haining et al. Photohemolysis. The comparative behavior of erythrocytes from patients with different types of porphyria
Zhou et al. Differential effects of cooling in hibernator and nonhibernator cells: Na permeation
Cook The action of potassium cyanide and potassium ferricyanide on certain respiratory pigments
Illner et al. Red blood cell sodium content and permeability changes in hemorrhagic shock
Anderson The use of radioactive phosphorus for determining circulating erythrocyte volumes
Pine et al. Sodium permeability and myocardial resistance to cell swelling during metabolic blockade
Maresca et al. Different temperature dependences of oxidative phosphorylation in the inner and outer layers of tuna heart ventricle
EP0986394B1 (en) Anti-coagulation of blood, blood plasma or synovial fluid products
Miles et al. Sodium and potassium content and membrane transport properties in red blood cells from newborn puppies
Nakache et al. Relationship between deformability of red blood cells and oxygen transfer: a modelized investigation
Auditore et al. Potassium transport in the acetylcholinesterase-deficient erythrocytes of paroxysmal nocturnal hemoglobinuria (PNH)
Sirs Influence of metabolism on uptake of CO and O2 by hemoglobin in erythrocytes
MEGEL et al. The relation of the adrenal to red blood cell fragility
Holton The alleged effect of acid phosphate on the anion permeability of erythrocytes